兴证国际(06058)发布公告，于2025年12月2日，本公司(作为借款方)与一家银行(作为贷款方)(贷款方)订 立融资函件(融资函件)以续期融资，贷款方同意向本公司提供最高额度为3500万美元的非承诺性循环贷 款融资。融资函件的终止日期为融资函件签立日期后12个月的日期或贷款方可能不时全权酌情决定并以 合理提前通知/须接受贷款方年度审阅的其他日期。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 China Industrial Securities International Financial Group Limited 興證國際金融集團有限公司 (於開曼群島註冊成立之有限公司) (股份代號：6058) 根據上市規則第13.18條之披露 本公告乃由興證國際金融集團有限公司(「本公司」)根據香港聯合交易所有限公司證券上市規 則(「上市規則」)第13.18條作出。 35,000,000美元非承諾性循環貸款融資 於本公告日期，興業證券間接擁有本公司2,388,631,644股權益，約佔本公司已發行股本之 59.72%。 只要上述履約責任的情況仍繼續存在，本公司將根據上市規則第13.21條於隨後之中期報告及 年度報告內作出有關披露。 承董事會命 興證國際金融集團有限公司 主席 熊博 1 茲提述本公司於二零二四年十二月三日刊發內容有關一筆最高總額為35,000,000美元之融資 公告(「二零二四年公告」 ...

FF301 公司名稱: 興證國際金融集團有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06058 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 20,000,000,000 | HKD | | 0.1 HKD | | 2,000,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 20,000,000,000 | HKD | | 0.1 HKD | | 2,000,000,000 | 本月底法定/註冊股本總額： HKD 2,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 ...

Core Viewpoint - The report from Xingzheng International initiates coverage on InnoCare Pharma (09606) with a "Buy" rating, highlighting its focus on the ADC field and strategic collaborations with leading global pharmaceutical companies like BioNTech to expedite clinical development globally [1] Recent Events - The company will host a R&D day on October 23, 2025, to present recent advancements in its ADC product pipeline and future directions [2] - BioNTech will hold its R&D day on November 11, 2025, showcasing InnoCare's original ADC pipeline in combination with immune antibodies like PD-L1/VEGF [2] - The clinical phase 2a of the autoimmune ADC pipeline DB-2304 (BDCA2 ADC) for systemic lupus erythematosus has completed its first patient dosing [2] - Results from the single-dose escalation phase of DB-2304 will be presented at the AIC 2025 conference, and data for DB-1310 targeting HR+/HER2- breast cancer will be disclosed at the SABCS 2025 [2] Global Clinical Progress - The BLA submission for DB-1303 (HER2 ADC) targeting HER2+ endometrial cancer is expected in 2026, with ongoing phase 3 trials for HR+/HER2 low-expressing breast cancer and plans for a BLA submission in China by the end of 2025 [3] - DB-1311 (B7H3 ADC) is currently in a global phase 2 basket trial for various solid tumors, with potential frontline treatment opportunities for SCLC through combination with PD-L1/VEGF dual antibodies [3] - The ADC pipeline in collaboration with BioNTech opens new market opportunities for ADC combination therapies, while DB-2304 shows promising tolerability and pharmacokinetic characteristics, positioning it as a potential first-in-class ADC drug in the autoimmune field [3]

Core Viewpoint - The report from Xingzheng International initiates coverage on Ying'en Bio-B (09606) with a "Buy" rating, highlighting the company's focus on the ADC sector and its strategic collaborations with leading global pharmaceutical companies like BioNTech to accelerate clinical development globally [1] Recent Events - The company will host a R&D day on October 23, 2025, to present recent advancements in its ADC product pipeline and future directions [2] - BioNTech will hold its R&D day on November 11, 2025, showcasing clinical plans for Ying'en Bio's original ADC pipeline in combination with immune antibodies such as PD-L1/VEGF [2] - The clinical phase 2a portion of the DB-2304 (BDCA2ADC) for systemic lupus erythematosus has completed its first patient dosing [2] - Results from the single-dose escalation phase of DB-2304 were selected for oral presentation at the AIC2025 conference [2] - The company plans to present global phase 1/2a data for the DB-1310 HER3ADC pipeline at the SABCS2025 [2] Global Clinical Progress of ADC Pipeline - The BLA for DB-1303 (HER2ADC) targeting HER2+ endometrial cancer is expected to be submitted in the U.S. in 2026, with ongoing global phase 3 trials for HR+/HER2 low-expressing breast cancer [3] - The company aims to submit the Chinese BLA for this indication by the end of 2025 [3] - DB-1311 (B7H3ADC) is currently in a global phase 2 basket trial for various solid tumors, including SCLC and CRPC, with potential frontline treatment opportunities being explored [3] - The collaboration with BioNTech on PD-L1/VEGF dual antibodies opens up future market opportunities for ADC combination therapies [3] - The clinical progress of the self-immune ADC pipeline DB-2304 has shown good tolerability and pharmacokinetic characteristics, positioning it as a potential first-in-class ADC drug in the autoimmune field [3]

Core Viewpoint - Xingsheng International (06058.HK) announced the sale of bonds worth USD 20 million in the open market, with a transaction value of approximately USD 20.54 million [1] Company Summary - As of November 27, 2025, Xingsheng International's stock closed at HKD 0.5, reflecting a 1.01% increase with a trading volume of 432,000 shares and a turnover of HKD 211,400 [1] - The market capitalization of Xingsheng International is HKD 1.98 billion, ranking 29th in the diversified financial industry [1] Key Financial Metrics - Return on Equity (ROE): 3.75%, compared to the industry average of -10.37%, ranking 37th out of 129 [1] - Market Capitalization: HKD 1.98 billion, against an industry average of HKD 6.788 billion, ranking 29th out of 129 [1] - Revenue: HKD 860 million, compared to the industry average of HKD 2.496 billion, ranking 27th out of 129 [1] - Net Profit Margin: 25.85%, significantly higher than the industry average of -1247.62%, ranking 40th out of 129 [1] - Debt Ratio: 79.31%, compared to the industry average of 40.41%, ranking 112th out of 129 [1]

Core Viewpoint - The company, Xingsheng International (06058), announced the sale of bonds amounting to $20 million by CISI Investment on the open market, with a total consideration of approximately $20.5441 million [1] Group 1 - The bond sale is scheduled for November 26, 2025 [1] - The nominal value of the bonds being sold is $20 million [1] - The total consideration received from the sale is about $20.5441 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 China Industrial Securities International Financial Group Limited 由於上市規則第14.07條項下有關出售事項的其中一項適用百分比率超過5%但低於25%，出 售事項構成本公司之須予披露交易，故須遵守上市規則第14章項下有關申報及公告之規定， 惟獲豁免遵守股東批准之規定。 董事會宣佈，於二零二五年十一月二十六日，CISI Investment於公開市場出售本金額為 20,000,000美元(相當於約157,000,000港元)之債券，代價為約20,544,107美元(相當於約 161,271,237港元)。 出售事項 出售債券詳情如下： 興證國際金融集團有限公司 (於開曼群島註冊成立之有限公司) (股份代號：6058) 有關出售債券之須予披露交易 出售事項 董事會宣佈，於二零二五年十一月二十六日，CISI Investment於公開市場出售本金 ...

Core Viewpoint - Xingsheng International (06058) has entered into two guarantees with Bank of China (Hong Kong) Limited, providing financial backing for its wholly-owned subsidiaries' non-committed financing letters, with a total guarantee amount of up to HKD 910 million and HKD 20 million respectively [1] Group 1 - The company has agreed to provide a guarantee (Guarantee A) to Bank of China (Hong Kong) for its subsidiary Xingsheng International Securities Limited, with a maximum amount of HKD 910 million [1] - The company has also agreed to provide a guarantee (Guarantee B) to Bank of China (Hong Kong) for its subsidiary Xingsheng International Futures Limited, with a maximum amount of HKD 20 million [1]

Core Viewpoint - The company, Xingsheng International, has entered into two guarantees with Bank of China (Hong Kong) Limited, providing financial backing for its wholly-owned subsidiaries' non-committed financing letters, with a total guarantee amount of up to HKD 910 million and HKD 20 million respectively [1][1][1] Summary by Category Company Guarantees - The company has agreed to provide a guarantee (Guarantee A) to Bank of China (Hong Kong) for the total liabilities of Xingsheng International Securities Limited, with a maximum amount not exceeding HKD 910 million [1] - Additionally, the company has established another guarantee (Guarantee B) for Xingsheng International Futures Limited, with a maximum amount not exceeding HKD 20 million [1]